

Congress of the United States
Washington, DC 20515

March 12, 2020

Alex Azar
Secretary
Department of Health and Human Services
200 Independence Avenue SW
Washington, DC 20201

Stephen Hahn
Commissioner
Food and Drug Administration
10903 New Hampshire Ave
Silver Spring, MD 20993

Dear Secretary Azar,

As concerns regarding our capacity to test patients with the 2019 Novel Coronavirus (COVID-19) continue to rise, the agency must take all steps necessary to ensure that all collected samples of the disease are able to be tested. We have heard from our research labs run by the University of California that they are capable of supporting the medical community but need further guidance about the steps that these labs—and labs across the country—could take to be in compliance with requirements in place under the current public health emergency declaration. Considering the urgency of mitigating the rising spread of COVID-19, we ask that you expedite assistance and regulatory guidance for new, simple tests that can be easily performed in the medical setting.

In Washington state, where community spread is rampant, researchers who had the capacity to support clinical lab work were prevented from doing so. Dr. Helen Y. Chu, as part of an infectious disease research project into the flu, had been collecting nasal swabs from Washington residents displaying flu-like symptoms throughout the Puget Sound region.¹ Dr. Chu offered her team's services to federal and state officials to help increase the state's ability to test patients who may have been exposed to COVID-19; however, her team was unable to do so. Reports explained that, "federal and state officials said the flu study could not be repurposed because **it did not have explicit permission from research subjects; the labs were also not certified for clinical work.**"² While patient privacy and clinical accuracy are of the utmost importance, it is time for the federal government to support research labs by providing the necessary waivers and expediting processes to remove restrictions that prevent labs and providers from testing samples collected from those displaying symptoms.

As another example, which is representative of many labs across America: the University of California Los Angeles's (UCLA) clinical lab is certified under the Clinical Laboratories Improvement Act and subsequent Amendments (CLIA) and is currently performing in-house testing following the Food and Drug Administration's (FDA) February guidance to help expedite testing.³ The FDA can issue an Emergency Use Authorization (EUA) to allow the use of medical products that are effective in "diagnosing, treating or preventing a disease or condition" when the Secretary of Health and Human Services (HHS) determines that there is a public health emergency.⁴ The policy issued in February specifically targets labs that develop and begin to use "validated" COVID-19 diagnostics before the FDA

¹ <https://www.nytimes.com/2020/03/10/us/coronavirus-testing-delays.html?searchResultPosition=1>

² <https://www.nytimes.com/2020/03/10/us/coronavirus-testing-delays.html?searchResultPosition=1>

³ <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics>

⁴ <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics>

has fully reviewed their EUA requests.⁵ The guidance focuses on those labs pursuing an EUA with the FDA that were already CLIA-certified. While we do not support loosening the restrictions around CLIA, which are essential to patient safety, many academic medical centers have research labs that use the same testing equipment and have more capacity but are not CLIA-certified. We would like to request that the Administration, acting through CMS, work with these labs, and all of those nationally that are similarly situated, to help them become certified so that they can help expand our testing capabilities.

In order to further expand testing capacity and spread, we must develop the same sort of simple, rapid tests being used in South Korea and other countries. Current domestic testing is very complex, done in certified labs with specialized equipment by highly trained individuals. Other countries have simpler tests, akin to a flu test that can easily be run by a primary care provider's office. We would urge you to work with the companies and the labs that are in the process of developing a simpler test,⁶ to help expedite an accurate, reliable, and valid test to the market as soon as possible.

Clinical accuracy is of the utmost importance, and we must do more to help ensure our communities are equipped and prepared to protect the health and safety of our communities. Continued delays in testing have made it virtually impossible for us to create a clear and precise picture of the scope of COVID-19's spread. As the number of cases continues to rise in California and across the country, we have a responsibility to ensure that we can test as many cases as possible – and this means assisting labs that stand ready to help.

Thank you for your attention to this critically important issue. Understanding the urgency of this request, we ask that you respond to this letter prior to March 18, 2020 with a clear and detailed report of your plan to expedite diagnostic testing.

Best,



KATIE PORTER
Member of Congress

JOHN GARAMENDI
Member of Congress



JERROLD NADLER
Member of Congress



MIKE THOMPSON
Member of Congress

*Please note that, out of an abundance of caution, only e-signatures were collected, so some signatures are not included.

⁵ <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-new-policy-help-expedite-availability-diagnostics>

⁶ <https://www.evaluate.com/vantage/articles/news/policy-and-regulation/few-groups-have-developed-covid-19-diagnostics-will>

GREGORY W. MEEKS
Member of Congress

DORIS MATSUI
Member of Congress

JARED HUFFMAN
Member of Congress

MARK TAKANO
Member of Congress

RAÚL M. GRIJALVA
Member of Congress

RUBEN GALLEGO
Member of Congress

COLIN Z. ALLRED
Member of Congress

MAX ROSE
Member of Congress

ANGIE CRAIG
Member of Congress

JOHN B. LARSON
Member of Congress

GERALD E. CONNOLLY
Member of Congress

TJ COX
Member of Congress



JERRY McNERNEY
Member of Congress

ALAN LOWENTHAL
Member of Congress



MARY GAY SCANLON
Member of Congress



GILBERT R. CISNEROS
Member of Congress



AYANNA PRESSLEY
Member of Congress

ABIGAIL SPANBERGER
Member of Congress



DARREN SOTO
Member of Congress



THOMAS R. SUOZZI
Member of Congress



TED W. LIEU
Member of Congress

MIKE LEVIN
Member of Congress



NYDIA VELÁZQUEZ
Member of Congress



SHARICE DAVIDS
Member of Congress



JAMES P. McGOVERN
Member of Congress


JAMIE RASKIN
Member of Congress



JUDY CHU
Member of Congress



ADAM SCHIFF
Member of Congress



LINDA T. SÁNCHEZ
Member of Congress



BOBBY L. RUSH
Member of Congress



JUAN VARGAS
Member of Congress

JOSEPH P. KENNEDY, III
Member of Congress



TERRI A. SEWELL
Member of Congress

ALCEE L. HASTINGS
Member of Congress

PETE AGUILAR
Member of Congress

DAVID SCOTT
Member of Congress

BONNIE WATSON COLEMAN
Member of Congress

DANNY K. DAVIS
Member of Congress

LUCY McBATH
Member of Congress

SUSIE LEE
Member of Congress

ELEANOR HOLMES NORTON
Member of Congress

KAREN BASS
Members of Congress

WILLIAM LACY CLAY
Member of Congress

YVETTE CLARK
Member of Congress



EMANUEL CLEAVER, II
Member of Congress

GRACE F. NAPOLITANO
Member of Congress



JIMMY PANETTA
Member of Congress



PETER WELCH
Member of Congress




CHRISSY HOULAHAN
Member of Congress

MARCIA L. FUDGE
Member of Congress



SEAN CASTEN
Member of Congress



BARBARA LEE
Member of Congress



ROSA DeLAURO
Member of Congress

DAVID PRICE
Member of Congress



DWIGHT EVANS
Member of Congress

MATT CARTWRIGHT
Member of Congress



PRAMILA JAYAPAL
Member of Congress


ANDY LEVIN
Member of Congress



SUSAN A. DAVIS
Member of Congress



NANETTE DIAZ BARRAGÁN
Member of Congress



ILHAN OMAR
Member of Congress



JAHANA HAYES
Member of Congress



HENRY C. "HANK" JOHNSON, JR.
Member of Congress



HAKEEM JEFFRIES
Member of Congress



GREG STANTON
Member of Congress

NORMA TORRES
Member of Congress



ALBIO SIRES
Member of Congress



RO KHANNA
Member of Congress



J. LUIS CORREA
Member of Congress



BRENDA LAWRENCE
Member of Congress




JULIA BROWNLEY
Member of Congress



SUZANNE BONAMICI
Member of Congress



CHELLIE PINGREE
Member of Congress



GRACE MENG
Member of Congress

A. Donald McEachin_{M.C.}

JIM COSTA
Member of Congress

A. DONALD McEACHIN
Member of Congress

A handwritten signature in black ink, reading "Lloyd Doggett". The signature is fluid and cursive, with a long horizontal stroke at the end.

LLOYD DOGGETT
Member of Congress

VICENTE GONZALEZ
Member of Congress

A handwritten signature in blue ink, reading "Peter A. DeFazio". The signature is stylized and cursive, with a prominent "P" and "D".

PETER A. DeFAZIO
Member of Congress

A handwritten signature in black ink, reading "Jim Himes". The signature is cursive, with a large "J" and "H".

JIM HIMES
Member of Congress